Temporary administration of recombinant relaxin-2 (serelaxin) in patients hospitalized with HF was associated with improved mortality 6 months after discharge.
with HF was associated with improved mortality 6 months after discharge.
The specific effects of serelaxin on vascular and myocardial structure and function in HF have not been studied.
In mice subjected to continuous 28-day heart failure stimulus of AngII and L-NAME, serelaxin was administered for 3 days (days 7 to 9), and both the acute effects during serelaxin infusion and the delayed effects after termination of serelaxin on cardiovascular structure and function were studied.
Temporary serelaxin improved vascular
fibrosis and myocardial capillary density and reduced resistance vessel constriction to potassium chloride during administration.
These effects unexpectedly persisted 19 days after discontinuation of serelaxin, despite continued exposure to AngII/L-NAME.
Serelaxin did not alter cardiac hypertrophy, geometry, or dysfunction at either time point.
These findings support that serelaxin predominantly affects vascular structure and function in the setting of HF.
SUMMARY
In patients hospitalized with acute heart failure, temporary serelaxin infusion reduced 6-month mortality through unknown mechanisms. This study therefore explored the cardiovascular effects of temporary serelaxin administration in mice subjected to the angiotensin II (AngII)/L-NG-nitroarginine methyl ester (L-NAME) heart failure model, both during serelaxin infusion and 19 days post-serelaxin infusion. Serelaxin administration did not alter AngII/L-NAME-induced cardiac hypertrophy, geometry, or dysfunction. However, serelaxin-treated mice had reduced perivascular left ventricular fibrosis and preserved left ventricular capillary density at both time points. Furthermore, resistance vessels from serelaxin-treated mice displayed decreased potassium chloride-induced constriction and reduced aortic fibrosis. These findings suggest that serelaxin improves high as 25% (3, 4) . The mechanisms promoting mortality after acute HF remain poorly understood, and consequently specific therapies to improve outcomes have not been successful.
The hormone relaxin has been identified recently as a potential therapy for acute HF. Relaxin also regulates multiple cardiovascular processes through interaction with the relaxin receptor, which is widely expressed in cardiovascular tissues (5) . In vascular tissue, relaxin induces potent dilation of systemic and coronary vessels, at least in part by a nitric oxidedependent mechanism, leading to increased arterial compliance, cardiac output, and renal blood flow (6-9). In patients with HF, acute treatment with recombinant human relaxin-2 (serelaxin) decreases systemic blood pressure and pulmonary capillary wedge pressure (10) . Circulating relaxin concentrations are elevated in humans with HF (8), further suggesting that relaxin normally opposes the maladaptive vasoconstricting effects of the renin angiotensin aldosterone system. In the recent serelaxin trial for treatment of acute HF, RELAX-AHF (Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure), patients hospitalized with acute HF were randomized to a 48-h infusion of serelaxin, which improved 1 of the 2 coprimary endpoints assessing dyspnea (3). Moreover, serelaxin treatment was associated with reduced mortality at 6 months after infusion, suggesting a prolonged benefit derived from short-term serelaxin treatment.
The delayed reduction in mortality after serelaxin infusion in patients with acute HF suggests that serelaxin confers benefits beyond acute vasodilation.
Accordingly, in addition to acute vasorelaxing effects, serelaxin has been shown to attenuate vascular and cardiac fibrosis in several disease models and to exert direct effects on cultured cardiac myocytes and fibroblasts (11) . Additionally, in humans with HF, short-term serelaxin treatment improved markers of renal function as well producing favorable effects on renal hemodynamic status (12, 13) . Supporting this, in the RELAX-AHF study, serum markers of cardiac injury, renal dysfunction, and liver damage were improved after serelaxin administration (13, 14) .
Whether temporary administration of serelaxin can produce prolonged benefits in HF, as was observed in humans, has not been tested experimentally, and the specific vascular and cardiac effects of serelaxin in the setting of acute and chronic HF remain unknown.
To address these questions, we examined the effects of serelaxin in the angiotensin II (AngII)/L-NGnitroarginine methyl ester (L-NAME) experimental model of HF, at time points designed to recapitulate the on-treatment and 6-month post-treatment time points reported in RELAX-AHF, but on a time scale suitable for mice (3, 15) . We chose the well-established 28-day AngII/L-NAME model using published concentrations of AngII/L-NAME that are well validated to produce a rise in systolic blood pressure (SBP). These doses induce myocardial damage within 4 days of administration (16, 17) , with myocardial fibrosis, cardiac myocyte hypertrophy, and reduction of LV systolic function present by 7 days and further progressive dysfunction after 28 days of AngII/ L-NAME. In the present study, we investigated: 1) the vascular and cardiac effects during serelaxin infusion initiated on day 7 during the acute phase of AngII/L-NAME HF; and 2) the effects on these parameters at day 28 of AngII/L-NAME, 18 days after cessation of serelaxin.
METHODS
A detailed description of methods is found in the Supplemental Appendix. Primer sequences can be found in Supplemental Table 1 .
ANIMAL STUDIES AND EXPERIMENTAL DESIGN. All mice were handled in accordance with National Institutes of Health standards, and all procedures were approved by the Tufts Medical Center Institutional Animal Care and Use Committee. The experimental timelines and designs are described in Figure 1A . We used 2 timelines: an "Acute:on-treatment" study and a "Chronic:post-treatment" study. Male, C57Bl6 mice 10 to 12 weeks of age were used in all studies. At day 0, wild-type mice received AngII via osmotic pump and L-NAME in drinking water continuously for 9 or 28 days. At day 7, mice were randomized to serelaxin (500 mg/kg/day) or vehicle (saline) administered by a second, 3-day osmotic pump. Mice were sacrificed on day 9 (2 days into serelaxin or vehicle infusion, Compared with historical untreated control mice of
the same age (15), LV mass was increased, and fractional shortening was impaired, indicating that AngII/ L-NAME induces pathological remodeling by day 9.
No differences were observed in these ultrasound parameters between vehicle-and serelaxin-treated groups at either time point ( Figure 2B ). Cardiomyocyte cross sectional area increased from day 9 to day 28 ( Figure 2C ) and did not differ significantly between serelaxin-or vehicle-treated groups at either time point.
BRIEF SERELAXIN INFUSION REDUCES PERIVASCULAR BUT NOT INTERSTITIAL CARDIAC FIBROSIS AND ENHANCES
CARDIAC ANGIOGENESIS IN THE AngII/L-NAME MODEL.
Cardiac fibrosis was already evident at day 9 of AngII/ L-NAME treatment, though the extent of interstitial fibrosis, measured by picrosirius red staining, did not differ between vehicle-and serelaxin-treated groups at day 9 or day 28 ( Figure 2C ). This is consistent with LV gene expression of markers of fibrosis (type-1 collagen, matrix metalloproteinase-2, and transforming growth factor-b), which did not differ between serelaxin-and vehicle-treated groups (Supplemental Figure 1) . Perivascular fibrosis, however, increased substantially from day 9 to day 28, but this was significantly attenuated in the serelaxintreated group compared with vehicle ( Figure 3A) . As a result, at day 28, perivascular fibrosis was significantly reduced in the serelaxin-treated compared with the vehicle-treated group.
Serelaxin-treated mice also displayed a significant increase in cardiac capillary density, as assessed by the density of CD31-positive capillaries per area of (A) In the Chronic:post-treatment study, telemeters were implanted on day 7. Blood pressure (BP) was recorded at baseline and throughout the duration of the experiment. In each experiment, angiotensin II (AngII) (800 ng/kg/min)/L-NG-nitroarginine methyl ester (L-NAME) (30 mg/kg/day in drinking water) treatment began at day 0. On day 7, mice were randomized to serelaxin or vehicle infusion by 3-day osmotic pump. Mice were sacrificed, and cardiac and vascular parameters were measured on day 9 in the Acute:on-treatment groups and on day 28 in McCarthy et al. 
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FIGURE 4 Serelaxin Treatment Decreases the Mesenteric Arteriolar Contractile Response to Potassium Chloride in the Angiotensin

II/L-NG-Nitroarginine Methyl Ester Heart Failure Model
Mesenteric resistance arterioles were isolated on day 9 or day 28 from mice treated with AngII/L-NAME, and with either serelaxiin or vehicle.
Vasoconstrictor and vasorelaxer responses were measured by wire myography. *p < 0.01 and †p < 0.05 for treatment effect within potassium chloride dose; ‡p < 0.05 for overall main effects of serelaxin versus vehicle (p ¼ 0.004, day 9; p ¼ 0.034, day 28). Data were compared using 2-factor repeated-measures analysis of variance with Tukey post hoc test. Figure 5C ). Interestingly, however, in the serelaxintreated group, vascular expression of type-1 collagen declined significantly from day 9 to day 28, resulting in a highly significant decrease in collagen expression in vessels treated with serelaxin compared with vehicle, at day 28 ( Figure 5C ). Furthermore, The abdominal aorta was isolated on day 9 (n ¼ 6) or on day 28 (n ¼ 5) of angiotensin II (AngII)/L-NG-nitroarginine methyl ester (L-NAME) infusion. Representative and summary data of aortic medial area from elastin-stained aortas (A) and aortic medial fibrosis from trichrome-stained aortas (B). Black arrows define the tunica media (medial area and degree of fibrosis was measured between arrows). Scale bars represent 1 mm. *p < 0.001; †p < 0.001 for main effects of treatment factor serelaxin versus vehicle; ‡p < 0.001 for main effects of time factor, day 9 versus day 28. (C) Messenger ribonucleic acid was isolated from aortas of mice treated with serelaxin or vehicle, and expression of fibrosis genes was measured by quantitative reverse transcription polymerase chain reaction. *p ¼ 0.018 serelaxin versus vehicle day 9; †p < 0.001, serelaxin day 28 versus vehicle day 28; ‡p ¼ 0.022 for main effects of time factor, day 9 versus day 28; §p < 0.001 for main effects of treatment factor serelaxin versus vehicle; kp ¼ 0.049 and ¶p ¼ 0.003, serelaxin day 9 versus serelaxin day 28. Connected single bars over days 9 and 28 indicate analysis of main effects between time points for vehicle and serelaxin in combination. Groups were compared using 2-factor analysis of variance with Tukey post hoc test. Col1 ¼ type 1 collagen; CTGF ¼ connective tissue growth factor; MMP2 ¼ matrix metalloproteinase 2; TGF ¼ transforming growth factor.
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Serelaxin Cardiovascular Effects in Heart Failure J U N E 2 0 1 7 : 2 8 5 -9 6 expression of matrix metalloproteinase-2, an enzyme that degrades collagen and hence opposes fibrosis, was increased 9-fold at day 9 in serelaxin-treated aortas compared with vehicle-treated aortas and then diminished compared with the vehicle-treated aortas by day 28 ( Figure 5C ).
DISCUSSION
In the present study, we examined the cardiac and Other studies in rodents have demonstrated reduction of interstitial fibrosis with serelaxin, but these studies involved chronic, rather than temporary, serelaxin infusion (20, 21) . Interestingly, 1 such study demonstrated reduced fibrosis in a myocardial infarction model, though similar to our findings, detected no significant alteration of LV function, hypertrophy, or structural remodeling with relaxin treatment (22) . We therefore interpret our findings to support that temporary serelaxin infusion does not exert direct effects on myocardial hypertrophy and remodeling in the AngII/L-NAME model. An alternative interpretation is that serelaxin does exert direct effects on cardiomyocyte function and remodeling in vivo, but that these effects were overwhelmed by the high dose and prolonged duration of AngII/L-NAME used in our study. As described earlier, we chose these doses and time points because they have been well validated previously to produce chronic HF and progressive cardiac and vascular remodeling. To our knowledge no other short-term pharmacological therapy has demonstrated long-term cardiac or vascular benefits in the AngII/L-NAME model. Thus, the impressive vascular benefits described here suggest that short-term serelaxin therapy can prevent the progression of vascular fibrosis and dysfunction despite persistent AngII/L-NAME treatment. However, future studies examining effects of serelaxin on cardiac and vascular dysfunction in additional models of acute and chronic HF will be informative.
SERELAXIN ENHANCES CAPILLARY DENSITY AND ATTENUATES THE PROGRESSION OF PERIVASCULAR
FIBROSIS IN RESPONSE TO AngII/L-NAME. Unlike interstitial fibrosis, which predominantly occurs as replacement for apoptotic myocytes (23) Unexpectedly, we observed that ex vivo resistance vessels from serelaxin-treated mice displayed
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